在乳腺癌中准细胞毒性淋巴细胞抗原4 (CTLA-4)
Maryam Jama1, Yasser Tabana1,2, Khaled H Barakat3,4
1Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada.
European journal of medical research
|July 3, 2024
概括
细胞毒性T-淋巴细胞关联蛋白4 (CTLA-4) 免疫疗法对乳腺癌 (BC) 是有前途的. 与单一疗法相比,组合疗法和新型抗体提供了更好的疗效和更低的毒性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症研究 癌症研究
背景情况:
- 乳腺癌 (BC) 仍然是全球癌症死亡的主要原因.
- 在BC中的瘤微环境中含有免疫细胞,如瘤透性淋巴细胞 (TIL) 和调节性T细胞 (Tregs),表明免疫性.
- 细胞毒性T-淋巴细胞相关蛋白4 (CTLA-4) 免疫疗法是公认的BC治疗方法,但在有效性和副作用方面面临挑战.
研究的目的:
- 审查乳腺癌中抗CTLA-4单克隆抗体 (mAb) 治疗的现状.
- 探索抗CTLA-4 mAb单疗与组合策略的疗效.
- 讨论新兴的CTLA-4治疗进展,临床试验和生物标志物在BC的应用.
主要方法:
- 对乳腺癌中抗CTLA-4疗法的现有文献的综述.
- 对CTLA-4 mAb单一治疗和组合治疗的临床前和临床数据的分析.
- 检查正在进行的临床试验和开发第二代CTLA-4抗体.
主要成果:
- 组合疗法 (例如Treg消耗,癌症疫苗,微生物组调节) 与CTLA-4 mAb单一治疗相比,显示出更好的抗瘤效果.
- 第二代CTLA-4抗体正在开发中,以增强抗瘤活性并最大限度地减少与免疫相关的不良事件 (irAEs).
- 生物标志物有可能优化BC的基于CTLA-4的治疗策略.
结论:
- 抗CTLA-4疗法,特别是组合疗法,是改善乳腺癌治疗结果的有希望的途径.
- 对新型CTLA-4抗体和生物标志物的持续研究和开发对于推进BC免疫治疗至关重要.
- 需要进行进一步的研究,以充分阐明CTLA-4向策略在治疗乳腺癌方面的潜力.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.7K
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
3.4K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy
509
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
Cytotoxic T Cells-mediated Immune Response
886
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
886
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
